Truqap is actually a kinase inhibitor that works by blocking pathways that support the cancer cells survive and expand, so lessens most cancers expansion. Truqap is from a category of medicines identified as an AKT inhibitor. Truqap gained FDA acceptance on November 17, 2023, soon after constructive final results from https://resmetirom35679.mybuzzblog.com/14482984/trastuzumab-deruxtecan-for-dummies